Melphalan vs polymelphalanum in ovarian cancer patients resistant to cyclophosphamide: A tentative statistical approach to balance risks and benefits

L. Morasca, M. Recchia, E. Gramellini, G. Bolis, C. Mangioni

Research output: Contribution to journalArticle

Abstract

A randomized trial based on a sequential analysis plan was started to check the activity of melphalan vs polymelphalanum in ovarian cancer patients resistant to cyclophosphamide. The trial was however closed in advance after treating only seven pairs of patients because of polymelphalanum toxicity. This decision is explained on statistical grounds in an attempt to provide a quantitative basis for balancing the toxicity found against the hoped-for benefits during the early phases of a clinical trial.

Original languageEnglish
Pages (from-to)817-820
Number of pages4
JournalEuropean Journal of Cancer (1965)
Volume13
Issue number8
DOIs
Publication statusPublished - 1977

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Melphalan vs polymelphalanum in ovarian cancer patients resistant to cyclophosphamide: A tentative statistical approach to balance risks and benefits'. Together they form a unique fingerprint.

  • Cite this